Snigdha Gadireddy
Rheumatology · Pine Bluff, ARNPI 1083268478
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 46.3% of the total. That places this record below the midpoint for rheumatology clinicians in AR, where the typical reported total is $4,419.
Across 69 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$587
- Amgen$276
- Mallinckrodt Hospital Products Inc.$153
- UCB, Inc.$83
- AstraZeneca$58
- Novo Nordisk$42
- plus $68 from 3 others
What the payments were for
- Food & beverage$1,267100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $587 |
| Amgen | 17 | $276 |
| Mallinckrodt Hospital Products Inc. | 5 | $153 |
| UCB, Inc. | 3 | $83 |
| AstraZeneca | 3 | $58 |
| Novo Nordisk | 2 | $42 |
| Akebia Therapeutics Inc | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Johnson & Johnson | 1 | $18 |
How this compares
$1,267 in reported general payments places this provider in the 35th percentile of 48 rheumatology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 22 | $1,026 |
| Celecoxib | 14 | $979 |
| Leflunomide | 13 | $786 |
| MethotrexateMethotrexate Sodium | 19 | $219 |
| Prednisone | 23 | $98 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Pine Bluff
- Maaman BashirPine Bluff$4K
- Russell BranumFort Smith$102K
- Cummins LueLittle Rock$76K
- Shailendra SinghSearcy$67K
- Christopher SonntagFayetteville$32K
- Jasen ChiLittle Rock$30K
- Richard HoukLittle Rock$25K
- Noha MohamedConway$19K
- Columbus BrownLittle Rock$18K
- David PetrosFayetteville$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.